As per a recent open‐label multicenter clinical analysis published in the Journal of Obstetrics and Gynaecology Research, Dydrogesterone, a retro‐progesterone found to be as a safe and effective treatment for dysmenorrhea.

A total of 31and 44 patients were selected for efficacy and safety analysis, respectively. Patients received one oral Dydrogesterone 5‐mg tablet twice daily for 21 days from 5th to 25th day of the menstrual cycle. All the individuals reviewed for the severity of menstruation‐associated nausea/vomiting, low back pain, headache, and lower abdominal pain, dysmenorrhea, total dysmenorrhea score, serum estradiol and progesterone levels, basal body temperature, visual analogue scale, and dysmenorrhea subscale scores.

The total dysmenorrhea score noticed at the baseline was 4.61, which went down with time after the Dydrogesterone administration, and the reduction was statistically meaningful at and after the 2nd cycle of menstruation. Menstruation-Associated nausea/vomiting, low back pain, headache, and lower abdominal pain in the estimated menstruation cycles reduced over time. Basal body temperature presented a biphasic pattern among 70% at baseline, 50% in 2nd menstruation cycle, and 61% in 5th menstruation cycle and all most half of the subjects may have had ovulation at the time of treatment. A total of 31.8% of patients showed adverse drug reactions. These findings reflect significant efficacy, clinically advantageous and safe modality among the dysmenorrhea patients.